Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats

Abstract

Necrotic bone exposure in the oral cavity has recently been reported in patients treated with nitrogen-containing bisphosphonates as part of their therapeutic regimen for multiple myeloma or metastatic cancers to bone. It has been postulated that systemic conditions associated with cancer patients combined with tooth extraction may increase the risk of osteonecrosis of the jaw (ONJ). The objective of this study was to establish an animal model of bisphosphonate-related ONJ by testing the combination of these risk factors. The generation of ONJ lesions in rats resembling human disease was achieved under the confluence of intravenous injection of zoledronate (ZOL; 35 µg/kg every 2 weeks), maxillary molar extraction, and vitamin D deficiency [VitD(−)]. The prevalence of ONJ in the VitD(−)/ZOL group was 66.7%, which was significantly higher (p < .05, Fisher exact test) than the control (0%), VitD(−) (0%), and ZOL alone (14.3%) groups. Similar to human patients, rat ONJ lesions prolonged the oral exposure of necrotic bone sequestra and were uniquely associated with pseudoepitheliomatous hyperplasia. The number of terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate–biotin nick-end label–positive (TUNEL+) osteoclasts significantly increased on the surface of post–tooth extraction alveolar bone of the VitD(−)/ZOL group, where sustained inflammation was depicted by [18F]fluorodeoxyglucose micro-positron emission tomography (µPET). ONJ lesions were found to be associated with dense accumulation of mixed inflammatory/immune cells. These cells, composed of neutrophils and lymphocytes, appeared to juxtapose apoptotic osteoclasts. It is suggested that the pathophysiologic mechanism(s) underpinning ONJ may involve the interaction between bisphosphonates and compromised vitamin D functions in the realm of skeletal homeostasis and innate immunity. © 2010 American Society for Bone and Mineral Research

Shown for reading. Its publisher allows quoting it, not republishing it.

References 56

1. 1.

   Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med. 1999;50:237-248.

   Not in our library10.1146/annurev.med.50.1.237

2. 2.

   Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897-907.

   Not in our library10.1093/annonc/mdj105

3. 3.

   Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.

   Not in our library10.1016/s0278-2391(03)00720-1

4. 4.

   Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534.

   Not in our library10.1016/j.joms.2004.02.004

5. 5.

   Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761.

   Not in our library10.7326/0003-4819-144-10-200605160-00009

6. 6.

   Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-8587.

   Not in our library10.1200/jco.2005.02.8670

7. 7.

   Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.

   Not in our library10.1056/nejm200507073530120

8. 8.

   Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 2007;86:1013-1021.

   Not in our library10.1177/154405910708601101

9. 9.

   Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.

   Not in our library10.1016/j.joms.2005.07.010

10. 10.

    Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.

    Not in our library10.1359/jbmr.0707onj

11. 11.

    Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-2410.

    Not in our library10.1016/j.joms.2007.08.003

12. 12.

    Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:4634-4638.

    Not in our library10.1200/jco.2008.16.2768

13. 13.

    Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2009;45:164-172.

    Not in our library10.1016/j.oraloncology.2008.04.013

14. 14.

    Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009;44:4-10.

    Not in our library10.1016/j.bone.2008.09.012

15. 15.

    Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol. 2008.

    Not in our library10.1111/j.1365-2141.2008.07214.x

16. 16.

    Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41:1164-1169.

    Not in our library10.1016/j.ejca.2005.01.017

17. 17.

    Ardine M, Generali D, Donadio M, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol. 2006;17:1336-1337.

    Not in our library10.1093/annonc/mdl045

18. 18.

    Lehrer S, Montazem A, Ramanathan L, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:389-391.

    Not in our library10.1016/j.tripleo.2008.01.033

19. 19.

    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.

    Not in our library

20. 20.

    Sukotjo C, Lin A, Song K, Ogawa T, Wu B, Nishimura I. Oral fibroblast expression of wound-inducible transcript 3.0 (wit3.0) accelerates the collagen gel contraction in vitro. J Biol Chem. 2003;278:51527-51534.

    Not in our library10.1074/jbc.m309616200

21. 21.

    Haber M. An exact unconditional test for the 2×2 comparative trial. Psychometrics Bull. 1986;99:129-132.

    Not in our library

22. 22.

    Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res. 2007;22:64-71.

    Not in our library10.1359/jbmr.061006

23. 23.

    Chatziiannou A, Qi J, Moore A, et al. Comparison of 3-D maximum a posterior and filtered backprojection algorithms for high-resolution animal imaging with microPET. IEEE Trans Med Imaging. 2000;19:507-512.

    Not in our library10.1109/42.870260

24. 24.

    Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155-160.

    Not in our library10.1111/j.1600-0714.2006.00391.x

25. 25.

    Surgeons AAoOaM. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-376.

    Not in our library10.1016/j.joms.2006.11.003

26. 26.

    Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.

    Not in our library10.1359/jbmr.0707onj

27. 27.

    Nishimura I, Damiani PJ, Atwood DA. Resorption of residual ridges (RRR) in rats. J Dent Res. 1987;66:1753-1757.

    Not in our library10.1177/00220345870660121101

28. 28.

    Hsieh YD, Devlin H, Roberts C. Early alveolar ridge osteogenesis following tooth extraction in the rat. Arch Oral Biol. 1994;39:425-428.

    Not in our library10.1016/0003-9969(94)90173-2

29. 29.

    Stratis A, Pasparakis M, Markur D, et al. Localized inflammatory skin disease following inducible ablation of IκB kinase 2 in murine epidermis. J Invest Dermatol. 2006;126:614-620.

    Not in our library10.1038/sj.jid.5700092

30. 30.

    Warter A, Walter P, Meyer C, Barriere P, Galatir L, Wilk A. Mandibular pseudocarcinomatous hyperplasia. Histopathology. 2000;37:115-117.

    Not in our library10.1046/j.1365-2559.2000.00949.x

31. 31.

    Akilov OE, Donovan MJ, Stepinac T, et al. T helper type 1 cytokines and keratinocyte growth factor play a critical role in pseudoepitheliomatous hyperplasia initiation during cutaneous leishmaniasis. Arch Dermatol Res. 2007;299:315-325.

    Not in our library10.1007/s00403-007-0765-6

32. 32.

    Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003;18:482-492.

    Not in our library10.1359/jbmr.2003.18.3.482

33. 33.

    Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res. 2008;23:544-551.

    Not in our library10.1359/jbmr.071207

34. 34.

    Bitto A, Burnett BP, Polito F, et al. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br J Pharmacol. 2008;155:896-905.

    Not in our library10.1038/bjp.2008.305

35. 35.

    Diaz-Curiel M, de la Piedra C, Romero FI, et al. Effect of risedronate on bone mass, remodelling and biomechanical strength in orchidectomized rats. Horm Res. 2008;70:93-99.

    Not in our library10.1159/000139151

36. 36.

    Nishimura I, Hosokawa R, Atwood DA. The knife-edge tendency in mandibular residual ridges in women. J Prosthet Dent. 1992;67:820-826.

    Not in our library10.1016/0022-3913(92)90592-x

37. 37.

    Anderson PH, Sawyer RK, Moore AJ, May BK, O'Loughlin PD, Morris HA. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res. 2008;23:1789-1797.

    Not in our library10.1359/jbmr.080616

38. 38.

    Nehme D, Rondeau E, Paillard F, et al. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant. 1989;4:123-128.

    Not in our library

39. 39.

    Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14:2387-2395.

    Not in our library10.1158/1078-0432.ccr-07-1430

40. 40.

    Jahangiri L, Devlin H, Ting K, Nishimura I. Current perspectives in residual ridge remodeling and its clinical implications: a review. J Prosthet Dent. 1998;80:224-237.

    Not in our library10.1016/s0022-3913(98)70116-7

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.